In response to the urgent need for new therapies that restore ventricular geometry and function, BioVentrix developed the Revivent-TC™ System, which facilitate Less Invasive Ventricular Enhancement™ (LIVE™). The Revivent TC™ System is indicated for patients with contiguous antero-septal or antero-apical scar and dilated LV. The LIVE™ procedure is beneficial because it:
Despite advances in percutaneous coronary intervention (PCI), approximately 35% of patients with acute coronary syndrome develop scar formation in the left ventricular for several reasons.1 To impact survival, PCI must be performed within the first 12 hours; however, 20% of patients seek intervention outside of this treatment window.2 As well, not all patients that receive PCI avoid scar formation. Nearly 20% of PCI patients with timely intervention still develop scar that involves greater than a third of their LV mass.3
For thousands of patients, scarred myocardium begins the adverse remodeling cycle of left ventricular dilatation. This increase in circumference and volume results in excessive wall tension, which triggers the progression of heart failure. For these patients, the Revivent TC™ Systems can provide an immediate reversal of the progression of the debilitating symptoms associated with heart failure.
*The Revivent-TC™ Ventricular Enhancement System requires regulatory approval and is not yet commercially available in the USA.